65/100 · Elevated
Manufactured by Immunex Corporation
Etanercept Adverse Events: Common Mild Reactions with Some Serious Concerns
1,356,881 FDA adverse event reports analyzed
Last updated: 2026-05-12
ETANERCEPT is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Immunex Corporation. Based on analysis of 1,356,881 FDA adverse event reports, ETANERCEPT has a safety score of 65 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for ETANERCEPT include DRUG INEFFECTIVE, INJECTION SITE PAIN, RHEUMATOID ARTHRITIS, ARTHRALGIA, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ETANERCEPT.
Etanercept has a safety concern score of 65 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 1,356,881 adverse event reports for this medication, which is primarily manufactured by Immunex Corporation.
The most commonly reported adverse events include Drug Ineffective, Injection Site Pain, Rheumatoid Arthritis. Of classified reports, 35.9% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Most common reactions include injection site pain and fatigue, indicating local and systemic effects.
Serious adverse events account for 35.9% of reports, highlighting the need for careful monitoring. A diverse range of reactions suggests potential for various side effects, necessitating comprehensive patient education.
Patients taking Etanercept should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Etanercept can cause injection site reactions and may interact with other drugs, so patients should be monitored for these effects and advised to report any unusual symptoms. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Etanercept received a safety concern score of 65/100 (elevated concern). This is based on a 35.9% serious event ratio across 591,566 classified reports. The score accounts for 1,356,881 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 407,746, Male: 139,055, Unknown: 1,013. The most frequently reported age groups are age 60 (12,738 reports), age 59 (12,505 reports), age 58 (12,486 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 591,566 classified reports for ETANERCEPT:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Etanercept can cause injection site reactions and may interact with other drugs, so patients should be monitored for these effects and advised to report any unusual symptoms.
If you are taking Etanercept, here are important things to know. The most commonly reported side effects include drug ineffective, injection site pain, rheumatoid arthritis, arthralgia, pain. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any serious adverse events immediately to their healthcare provider. Follow prescribed dosing and administration instructions to minimize the risk of injection site reactions. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor etanercept for safety, and updates are regularly issued based on new data.
The FDA has received approximately 1,356,881 adverse event reports associated with Etanercept. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Etanercept include Drug Ineffective, Injection Site Pain, Rheumatoid Arthritis, Arthralgia, Pain. By volume, the top reported reactions are: Drug Ineffective (75,053 reports), Injection Site Pain (56,662 reports), Rheumatoid Arthritis (46,177 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Etanercept.
Out of 591,566 classified reports, 212,159 (35.9%) were classified as serious and 379,407 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Etanercept break down by patient sex as follows: Female: 407,746, Male: 139,055, Unknown: 1,013. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Etanercept adverse events are: age 60: 12,738 reports, age 59: 12,505 reports, age 58: 12,486 reports, age 61: 12,001 reports, age 57: 11,860 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Etanercept adverse event reports is Immunex Corporation. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Etanercept include: Injection Site Erythema, Fatigue, Pain In Extremity, Joint Swelling, Psoriasis. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Etanercept to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Etanercept has a safety concern score of 65 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Most common reactions include injection site pain and fatigue, indicating local and systemic effects.
Key safety signals identified in Etanercept's adverse event data include: Injection site reactions are frequent, with erythema, swelling, and pruritus being common.. Infections, particularly respiratory and urinary tract infections, are notable serious adverse events.. There is a significant number of reports related to musculoskeletal pain and stiffness, indicating potential for joint issues.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Etanercept can cause injection site reactions and may interact with other drugs, so patients should be monitored for these effects and advised to report any unusual symptoms. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Etanercept.
Patients should report any serious adverse events immediately to their healthcare provider. Follow prescribed dosing and administration instructions to minimize the risk of injection site reactions.
Etanercept has 1,356,881 adverse event reports on file with the FDA. Serious adverse events account for 35.9% of reports, highlighting the need for careful monitoring. The volume of reports for Etanercept reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor etanercept for safety, and updates are regularly issued based on new data. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Immunex Corporation and compare their safety profiles:
The following drugs share commonly reported adverse reactions with ETANERCEPT:
Drugs related to ETANERCEPT based on therapeutic use, drug class, or shared indications: